Reply to the letter from Janssen et al.
1994
Effects of Low-Dose Interleukin-2 on T-Cell Activation
publication
Author Information
Author(s): L.T. Vlasveld, E.M. Rankin, C.J.M. Melief
Primary Institution: The Netherlands Cancer Institute
Hypothesis
Does continuous infusion of low-dose recombinant interleukin-2 lead to T-cell activation?
Conclusion
The study found transient T-cell activation after one week of low-dose rIL-2 treatment, but limited anti-tumor effects were observed.
Supporting Evidence
- Continuous treatment with rIL-2 increases natural killer cells and their activity.
- T-cell activation signs were observed after one week of treatment.
- The anti-tumor effect of rIL-2-induced T-cell activation has not been demonstrated in humans.
Takeaway
When patients received a low dose of a treatment called interleukin-2, their immune cells called T-cells became active for a short time, but it didn't help fight cancer much.
Methodology
The study involved continuous infusion of low-dose rIL-2 and monitoring T-cell activation markers.
Limitations
The anti-tumor effect of T-cell activation was not demonstrated in patients.
Want to read the original?
Access the complete publication on the publisher's website